Ceftriaxone / Clindamycin (Systemic Use)

Mechanism

Pharmacological Class and Group

Antimicrobial association of a third-generation cephalosporin with a broad spectrum and long half-life (Ceftriaxone) with an antibiotic from the lincosamine family (Clindamycin) with excellent anaerobic coverage and suppressor of bacterial toxins.

Mechanism of Action

This drug combination is used in mixed polymicrobial bacterial infections of the neck to achieve synergistic coverage against Gram-positive cocci, Gram-negative bacilli and strict anaerobic gas-producing bacteria:

• Ceftriaxone: Beta-lactam bactericidal antibiotic that inhibits bacterial cell wall synthesis by irreversibly binding to penicillin-binding proteins (PBP-3) in Gram-negative and Gram-positive bacteria. It prevents terminal bacterial transpeptidation of the peptidoglycan layer, inducing osmotic lysis of the pathogen. It is resistant to many beta-lactamases from the group of Gram-negative bacteria.
• Clindamycin: Bacteriostatic or bactericidal antibiotic that inhibits the synthesis of bacterial proteins by reversibly binding to the 50S subunit of the bacterial ribosome, blocking the enzyme peptidyltransferase and the subsequent elongation of the cellular polypeptide chain:
  • It presents exceptional coverage against anaerobic bacteria in the oral cavity (such as Fusobacterium nucleatum, Prevotella, and Peptostreptococcus).
  • Inhibits the synthesis of bacterial exotoxins and stops the local release of harmful bacterial inflammatory mediators directly.

Synergistic Profile in Ludwig's Angina

In infections of the submandibular and sublingual spaces (Ludwig's Angina), the causative microbiota is usually of mixed dental or tonsillar origin, involving anaerobic streptococci and strict Gram-negative anaerobic bacilli:

Ceftriaxone: Coverage of aerobic and inflammatory Gram-negatives Clindamycin: Coverage of strict anaerobes of the mouth + Suppression of toxins

The intravenous combination of ceftriaxone and clindamycin provides early and optimal empirical coverage, facilitating the control of diffuse cellulitis and limiting the spread of tissue necrosis towards the mediastinum.

Pharmacokinetics

High Resolution Pharmacokinetics

• Ceftriaxone:
  • Administration: Intravenous or deep intramuscular.
  • Distribution: Excellent penetration into soft tissues of the neck, submandibular space and bone periosteum. High binding to plasma albumin (85-95%).
  • Metabolism: It is not metabolized in the liver; It is partially transformed bacterially in the intestinal lumen to inactive metabolites.
  • Excretion: Mixed excretion: 60% via kidney unchanged in urine; 40% through bile and feces.
  • Half-life (t_1/2): Prolonged, from 6 to 8 hours, which allows dosing in a single daily dose in adults.
• Clindamycin:
  • Administration: Intravenous in slow infusion or orally (good bioavailability of 90%).
  • Distribution: It penetrates prominently into the muscular and subcutaneous cellular tissue and into the matrix of the inflamed maxillary bone. It does not cross the blood-brain barrier with healthy meninges. Moderate plasma protein binding (92-94%).
  • Metabolism: Extensive hepatic metabolism via cytochrome CYP3A4 to active metabolites such as clindamycin sulfoxide.
  • Excretion: Majority elimination through bile and feces, only 10% is actively recovered unchanged through the kidneys.
  • Half-life (t_1/2): 2.4 to 3 hours in adults.

Indicators and dose

Clinical Indications and Off-Label Uses

• Infections of the Deep Spaces of the Neck: Ludwig's angina, submandibular, retropharyngeal and parapharyngeal abscesses that directly threaten the patency of the upper airway.
• Suppurative Complications of Otitis and Sinusitis: Acute mastoiditis with osteitis, thrombosis of the sigmoid sinus or postseptal or preseptal orbital cellulitis secondary to ethmoidal rhinosinusitis.
• Perioperative Prophylaxis in Major Head and Neck Surgery: Prevention of infections and salivary fistulas in pharyngolaryngectomies, cervical dissections and implantation of free microvascular flaps.

Dosage and Clinical Adjustment

Ceftriaxone (Intravenous):

• Adults: 1 g to 2 g by slow IV or diluted infusion once daily (every 24 hours). In severe neck infections, the dose of 2 g per day is preferred.
• Children (>28 days): 50 mg/kg/day to 80 mg/kg/day slowly intravenously once daily.

Clindamycin (Intravenous Route or Oral Route):

• Intravenous Route (Adults): 600 mg to 900 mg intravenously administered as a slow infusion (over 30 minutes, never as a direct bolus) every 8 hours.
• Oral Route (Maintenance / Discharge): 300 mg to 450 mg orally every 8 hours, swallowed with plenty of water to avoid retention esophagitis.
• Children (>1 month): 20 mg/kg/day to 40 mg/kg/day divided into 3 or 4 doses per day intravenously.

Adjustment in Renal or Liver Failure:

• Ceftriaxone: Does not require adjustment if there is only renal failure (even on hemodialysis) or isolated liver failure. In case of severe simultaneous renal and hepatic failure, it is advisable to reduce the maximum dose to 2 g per day.
• Clindamycin: Does not require dose adjustment in renal failure. In severe decompensated liver cirrhosis, it is advisable to monitor drug levels due to the prolongation of the hepatic elimination half-life.

Security

Absolute and Relative Contraindications

Contraindications of Ceftriaxone

• History of severe immediate hypersensitivity to cephalosporins or penicillins.
• Premature neonates or neonates with neonatal jaundice: Ceftriaxone competitively displaces indirect bilirubin from plasma albumin, increasing the risk of bilirubin encephalopathy (kernicterus).
• Coadministration with intravenous calcium solutions (such as Lactated Ringer's) in neonates due to the risk of fatal precipitation of the ceftriaxone-calcium complex in the lungs and kidneys.

Contraindications of Clindamycin

• Known hypersensitivity to lincosamines (lincomycin/clindamycin).
• Personal history of Clostridioides difficile colitis or active inflammatory bowel disease.

Adverse Effects (ADR) and Specific Toxicity

• Ceftriaxone (Common 1%-10%): Transient diarrhea, elevation of transaminases, transient neutropenia. Biliary sludge (iatrogenic cholelithiasis): due to the precipitation of the calcium salt of ceftriaxone in the gallbladder, manifesting with pain in the right upper quadrant (self-limited after withdrawing the antibiotic).
• Clindamycin (Very common >10%): Mild gastrointestinal disorders (colicky abdominal pain, flatulence).
• Clindamycin (Common 1%-10%): Pseudomembranous colitis, generalized maculo-papular skin rashes, local pain and phlebitis at the site of rapid intravenous infusion.

Critical Toxicity: Clostridioides difficile colitis induced by Clindamycin

Clindamycin is one of the antibiotics with the highest reported risk of inducing pseudomembranous colitis due to radical alteration of the bacterial microbiota of the colon, favoring the hypervirulent proliferation and degranulation of toxins A and B of Clostridioides difficile. The condition presents with profuse watery diarrhea (more than 10 foul-smelling stools a day), high fever, crampy abdominal pain and severe leukocytosis.

Use of Clindamycin Loss of normal colon microbiota Superinfection of C. difficile

The drug should be immediately suspended, confirmed by detection of toxins in feces, and immediate empirical treatment initiated with oral vancomycin (125 mg every 6 hours) or oral fidaxomicin to avoid the development of toxic megacolon and intestinal perforation.

Drug Interactions of Clinical Relevance

• Neuromuscular Blockers (Atracurio, Vecuronium): Clindamycin enhances the blockade of the neuromuscular junction, prolonging transient respiratory paralysis in the immediate postoperative period. The patient's extubation must be rigorously monitored.
• Systemic aminoglycoside antibiotics: Synergistic against opportunistic bacteria, but requires monitoring of renal function due to mild additive risk of nephrotoxicity.

Safety in Pregnancy and Breastfeeding

• Pregnancy: Compatible. Both antibiotics are FDA category B, being the therapeutic choice if parenteral regimens are required in pregnant women with neck infections of dental origin.
• Breastfeeding: Compatible. They are excreted in breast milk in minimal quantities; Monitor the infant for the possible appearance of diarrhea, colic or oral candidiasis.